12 news items
RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis
ABBV
4 Jun 24
untreated, may lead to joint damage.5-6 Despite treatment advancements, achieving long-term remission
AbbVie Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
ABBV
ALXO
ANVS
3 Jun 24
-endoscopic mucosal improvement.
Per AbbVie, endoscopic improvement may lead to potential long-term benefits, including lower risk
AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
ABBV
31 May 24
show that patients with moderately to severely active UC can strive for long-term management goals that go beyond symptom control, including histologic
AbbVie Completes Acquisition of Landos Biopharma
ABBV
LABP
23 May 24
to severe UC with a long-term extension (LTE) period. All subjects will be randomized to receive either 250 mg or 750 mg immediate release NX-13
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation
ABBV
JNJ
LLY
21 May 24
and collaborations, which are vital for long-term growth.
3. Financial Stability: The recent share purchase agreement
purjh3encc y8ufq3s99yrzkpxzn9yllg5u2
ABBV
BMY
17 May 24
expects robust growth to resume in 2025, with projections aligning with management’s long-term guidance of a high single-digit compound annual
1k8fdxw8tyk5rwmr0uqyedhqymj 0w296vv2nus227btwcn7v4l1
ABBV
17 May 24
as long-term care goals, in a way that can be felt by the patient and measured by their health care team
ei8ue30ca0ry65x8t20341qzad1eslj7owypeprz7it1kg
ABBV
25 Apr 24
. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label
l8904ghj4qag5bohugmm46
ABBV
12 Apr 24
an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant
wof4tet r8elk
ABBV
12 Apr 24
, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine
snne4t50pye38mt4fmawg0jcp1lehpwffeu4
ABBV
12 Apr 24
extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic
3rrzbu7mgm6ed181bol4
ABBV
LABP
25 Mar 24
-week induction study evaluating 80 patients with moderate to severe UC with a long-term extension (LTE) period. All subjects will be randomized
- Prev
- 1
- Next